BioNexus Gene Lab Corp Files 8-K/A Amendment

Ticker: BGLC · Form: 8-K/A · Filed: Jul 5, 2024 · CIK: 1737523

Bionexus Gene Lab CORP 8-K/A Filing Summary
FieldDetail
CompanyBionexus Gene Lab CORP (BGLC)
Form Type8-K/A
Filed DateJul 5, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$35,000
Sentimentneutral

Sentiment: neutral

Topics: amendment, corporate-governance, officer-changes

Related Tickers: BGLL

TL;DR

BioNexus Gene Lab Corp amended its 8-K filing regarding director changes and executive pay.

AI Summary

BioNexus Gene Lab Corp. filed an amendment (8-K/A) on July 5, 2024, to a report originally dated March 26, 2024. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.

Why It Matters

This filing indicates updates to the company's board of directors and executive compensation, which can signal changes in corporate strategy or governance.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings, especially those concerning director and officer changes, can indicate internal shifts that may impact the company's future performance.

Key Players & Entities

FAQ

What specific items are being amended in this 8-K/A filing?

This 8-K/A filing amends items related to the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.

What was the original report date that this amendment refers to?

The original report date that this amendment refers to is March 26, 2024.

What is the filing date of this amendment?

The filing date of this amendment is July 5, 2024.

In which state is BioNexus Gene Lab Corp. incorporated?

BioNexus Gene Lab Corp. is incorporated in Wyoming.

What is the SIC code for BioNexus Gene Lab Corp.?

The Standard Industrial Classification (SIC) code for BioNexus Gene Lab Corp. is 8071, which falls under SERVICES-MEDICAL LABORATORIES.

Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-07-05 17:15:19

Key Financial Figures

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 10.1 Amendment to the Service Contract between the Company and Mr. Su-Leng Tan Lee dated June 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: July 5, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 3

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing